Skip to content

    Tarsons Products

    TARSONS
    Healthcare·25 May 2026
    Management Summary

    Tarsons Products reported a resilient Q4 and FY26, with consolidated revenue growing 7.3% and 7.7% YoY respectively, driven by strong domestic performance. However, export business faced headwinds due to geopolitical tensions, leading to a 13.4% decline in Q4. Margins were pressured by rising raw material costs and higher depreciation from new capex, though Adjusted Cash PAT saw robust 21.4% YoY growth. The company anticipates full commissioning of its capex program in H1 FY27, expecting initial benefits from higher volumes and improved product availability.

    Highlights

    5

    • Q4 FY26 Consolidated Revenue at INR 120.9 crores, reflecting a 7.3% YoY growth.

    • FY26 Consolidated Revenue reached INR 422.5 crores, registering a 7.7% YoY growth.

    • Domestic business demonstrated strong resilience with approximately 12% YoY growth in Q4 FY26.

    • FY26 Adjusted Cash PAT stood at INR 112 crores, representing a strong growth of 21.4% YoY.

    • The entire capex program is expected to be fully commissioned during the first half of the current financial year, enhancing production capacities.

    Concerns

    4

    • Export business declined by 13.4% in Q4 FY26 due to geopolitical tensions and supply chain disruptions.

    • Gross margins and EBITDA margins were impacted by a significant increase in raw material prices during February and March.

    • PAT for both Q4 and FY26 was impacted by higher depreciation and interest costs associated with the new capex.

    • FY27 PAT is likely to remain at a relatively moderate level due to higher depreciation and interest costs.

    Key financials

    Metrics

    7

    Periods

    2

    Headline

    5
    • Consolidated Revenue
      ₹120.9 Cr
      YoY+7.3%
    • Consolidated EBITDA
      ₹34.3 Cr
    • Consolidated EBITDA Margin
      28.3%
    • Consolidated PAT
      ₹14.3 Cr
    • Consolidated Adjusted Cash PAT
      ₹33 Cr
      YoY+9.3%

    FY26

    2
    • Consolidated Revenue
      ₹422.5 Cr
      YoY+7.7%
    • Consolidated Adjusted Cash PAT
      ₹112 Cr
      YoY+21.4%

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Capex

    ₹20 crores

    Guidance & targets

    8
    CategoryTargetPriority
    Capex
    CWIP conversion to assets
    INR 158 crores
    		High
    Depreciation
    Standalone Depreciation
    INR 105-110 crores
    		High
    Depreciation
    Consolidated Depreciation
    ~INR 110 crores
    		Medium
    Profitability
    PAT level
    relatively moderate level
    		Medium
    Profitability
    PAT percentage
    4-5%
    		Medium
    Gross Margin
    Q1 FY27 Gross Margin
    not below 65%
    		Medium
    Capacity
    Capex program commissioning
    fully commissioned
    		High
    Growth
    Company growth trajectory
    outperforming internal expectations
    		Medium

    Raw material price normalization

    next quarter
    CurrentSignificant spike in raw materials, impacting margins
    TargetNormalization of raw material prices

    Why it matters

    Raw material prices directly impact gross and EBITDA margins, and their normalization is key for margin recovery.

    Aryan Sehgal: I would not be able to answer that clearly because at this point of time, we have a significant spike in raw materials as we speak, right? This has been prevalent for the last 8 to 10 weeks, from the beginning middle of March. So, it depends on how soon there will be normalized conditions because these large raw material spikes are primarily attributed to manufacturers in Asia and not so much to manufacturers in the U.S.

    How to verify

    key_financials.metrics[label='Gross Margin']

    Risks & concerns

    5
    RiskSeverity

    Export business decline due to geopolitical tensions

    Export business declined by 13.4% in Q4 FY26 largely due to ongoing geopolitical tensions and warlike situation in the Middle East, disrupting global supply chains. — Management acknowledged

    high

    Raw material price volatility and supply chain disruptions

    Significant increase in raw material prices in Feb/March, driven by commodity price movements and global supply chain disruptions, impacting gross and EBITDA margins. Non-availability of containers and elevated freight costs also contributed. — Management acknowledged

    high

    Impact of higher depreciation and interest costs on PAT

    PAT for Q4 and FY26 was impacted by higher depreciation and interest costs following the commissioning of new capex, with FY27 PAT expected to remain moderate. — Management acknowledged

    medium

    Price competition from domestic and international players

    The company faces price competition from domestic players and strong, high-quality Chinese manufacturers in international markets, making it challenging to pass on full cost increases. — Both acknowledged

    medium

    Operational challenges in implementing price hikes

    Difficulty in frequently altering price lists for distributors and customers in India due to the yearly process of printing and circulating price books, leading to potential loss of credibility and stocking issues. — Management acknowledged

    medium

    Q&A highlights

    8

    “Aryan Sehgal: No, I think it depends on the customer segments, what we are looking at. There is the market internationally is quite large and is available to wide range of companies selling in the international market. So, we do receive a lot of price competition. There is a lot of price competition from domestic players in India exporting as well as from Chinese players.”

    Addresses how Tarsons competes on price and value in a competitive global market, acknowledging the presence of low-cost players.

    asked by Rushabh Shah

    2 min read6 chapters

    Detailed Narrative

    01

    Q4 & FY26 Performance Overview

    Tarsons Products achieved its highest ever quarterly revenue in Q4 FY26, reaching INR 121 crores, a 7.4% year-on-year growth. For the full fiscal year 2026, revenue stood at INR 426 crores, growing 7.7% year-on-year. The company outperformed overall industry growth trends, which saw a modest 3% quarter-on-quarter growth and an 8% year-on-year decline, while Tarsons grew 16% QoQ and 4.5% YoY respectively. Consolidated Adjusted Cash PAT for FY26 was INR 112 crores, marking a strong 21.4% year-on-year growth.

    02

    Domestic vs. Export Business Dynamics

    The domestic business demonstrated strong resilience, delivering approximately 12% year-on-year growth in Q4 FY26 and 7% for the full year. This reflects continued demand momentum and strengthening market presence in India. In contrast, the export business experienced a 13.4% decline in Q4 FY26 and only 3% growth for FY26, primarily due to geopolitical tensions in the Middle East, which disrupted global supply chains, leading to shipment delays and elevated freight costs.

    03

    Margin Pressures and Raw Material Volatility

    Both gross and EBITDA margins witnessed a decline in Q4 and FY26, largely due to a significant increase in raw material prices during February and March. This was driven by commodity price movements and global supply chain disruptions. Standalone gross margin for Q4 FY26 was 58.5%. The company is gradually increasing prices to mitigate the impact, but full cost pass-through is challenging due to competitive pressures and the operational difficulty of frequent price changes in the Indian market.

    04

    Capex Program and Future Growth Drivers

    Tarsons is nearing the completion of its largest-ever capex program, with the entire program expected to be fully commissioned during the first half of FY27. INR 158 crores of Capital Work-in-Progress (CWIP) will be moved to main assets in FY27. Beyond this, no major capex is planned, only approximately INR 20 crores for maintenance in FY27. These new facilities are expected to significantly enhance production capacities and diversify the product basket, positioning the company for strong revenue growth and operating leverage in the medium term.

    05

    Cell Culture and New Product Ramp-up

    The company has commercially launched certain cell culture lines, with a slower initial ramp-up expected as customers conduct trials and onboard Tarsons as a vendor. Significant momentum for the cell culture business is anticipated towards the end of FY27 or beginning of FY28. Tarsons expects initial benefits from the new capacities to reflect in FY27 through higher volumes and improved product availability, with substantial scale-up projected over the next 4-5 years for these new lines.

    06

    Competitive Landscape and Pricing Strategy

    Tarsons operates in a competitive environment with both domestic and international players, including strong Chinese manufacturers. While the rupee depreciation makes imports more expensive, favoring 'make in India' producers, the company faces challenges in passing on the full impact of raw material price hikes. Management is cautiously implementing gradual price increases, balancing cost recovery with maintaining market share and customer relationships, acknowledging that a 60-70% raw material price hike cannot be fully absorbed.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.